MARKET

PSTV

PSTV

Plus Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8657
0.0000
0.00%
Closed 16:41 01/26 EST
OPEN
0.8788
PREV CLOSE
0.8657
HIGH
0.9300
LOW
0.8478
VOLUME
409.14K
TURNOVER
--
52 WEEK HIGH
5.42
52 WEEK LOW
0.8118
MARKET CAP
18.33M
P/E (TTM)
-0.5674
1D
5D
1M
3M
1Y
5Y
5 Stocks To Watch For January 18, 2022
 
Benzinga · 01/18 10:03
BRIEF-Plus Therapeutics Inc On Jan 14 Entered Into An Equity Distribution Agreement With Canaccord Genuity Llc
reuters.com · 01/14 21:22
18 Stocks Moving in Friday's Pre-Market Session
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) shares rose 17.6% to $0.8350 in pre-market trading after dropping around 9% on Thursday.
Benzinga · 01/14 11:52
56 Biggest Movers From Friday
Gainers Hour Loop, Inc. (NASDAQ: HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share.
Benzinga · 01/10 09:47
Absci, Quoin Pharmaceuticals lead healthcare gainers; Odonate, Alterity among losers
Gainers: Absci ABSI +39%. Quoin Pharmaceuticals (NASDAQ:QNRX) +13%. Singular Genomics Systems (NASDAQ:OMIC) +13%. Personalis (NASDAQ:PSNL) +11%. Simulations Plus (NASDAQ:SLP) +10%. Losers: Odonate Therapeutics ODT -25%. Alterity Therapeutics (NASDAQ:ATHE) ...
Seekingalpha · 01/07 15:00
Plus Therapeutics to Participate in Upcoming January Conferences
AUSTIN, Texas, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that...
GlobeNewswire · 01/07 12:00
Plus Therapeutics in pact with University of Texas for cancer therapeutics
Plus Therapeutics (NASDAQ:PSTV) has added ~6.2% in the pre-market after the company further expanded its pipeline for experimental cancer following a partnership with The University of Texas Health Science Center at San
Seekingalpha · 01/06 12:38
BRIEF-Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline
reuters.com · 01/06 12:20
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PSTV. Analyze the recent business situations of Plus Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PSTV stock price target is 6.67 with a high estimate of 7.00 and a low estimate of 6.00.
High7.00
Average6.67
Low6.00
Current 0.8657
EPS
Actual
Estimate
-0.54-0.40-0.27-0.13
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 34
Institutional Holdings: 1.30M
% Owned: 6.15%
Shares Outstanding: 21.18M
TypeInstitutionsShares
Increased
4
131.06K
New
0
0
Decreased
6
289.19K
Sold Out
4
150.36K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.73%
Pharmaceuticals & Medical Research
-0.45%
Key Executives
Non-Executive Chairman/Independent Director
Richard Hawkins
President/Chief Executive Officer/Director
Marc Hedrick
Chief Financial Officer
Andrew Sims
Other
Norman LaFrance
Independent Director
Howard Clowes
Independent Director
Robert Lenk
Independent Director
Greg Petersen
Independent Director
Annigje Van Es-johansson
No Data
About PSTV
Plus Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.

Webull offers kinds of Plus Therapeutics Inc stock information, including NASDAQ:PSTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTV stock methods without spending real money on the virtual paper trading platform.